Cipla Ltd.

In a bid to implement research oriented projects, Pharma major Cipla is planning to invest about Rs 600 crore in research and development (R&D) in FY15. The company has undertaken a major expansion of its R&D Centre, with new buildings and facilities at Vikhroli in Mumbai. The company’s development and regulatory approval processes are on track. Currently, there are over 200 development projects underway indicating a robust pipeline.

The company has been granted many patents in the field of pharmaceuticals. The company’s R&D expenses increased from 5.1 per cent of its total revenue in FY13 to 5.4 per cent in FY14.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.